R. Robinson

4.5k citations

71 papers · 2.7k indexed · 1 hit paper · h-index 24

Impact in

Organic Chemistry top 2%
- Synthesis and Biological Evaluation
- Quinazolinone synthesis and applications
- Synthesis and biological activity
- Multicomponent Synthesis of Heterocycles
Molecular Biology top 10%
- PI3K/AKT/mTOR signaling in cancer
- Protein Kinase Regulation and GTPase Signaling
- Biochemical and Molecular Research

Papers in

Biochemistry 8
Organic Chemistry 17
- Quinazolinone synthesis and applications 11
- Synthesis and Biological Evaluation 8

Co-authors: John Gallagher Hans E. Huber Deborah Defeo-Jones Stanley F. Barnett Raymond E. Jones George D. Hartman Zhijian Zhao Craig W. Lindsley
Journals: Bioorganic & Medicinal Chemistry Letters (21 papers)Nature (7 papers)Clinica Chimica Acta (5 papers)Journal of Clinical Pathology (3 papers)Annals of the Rheumatic Diseases (3 papers)
Partner nations: United States United Kingdom Czechia

In The Last Decade

R. Robinson

70 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

The Imperialism of Free Trade 1953 · 351 citations

Peers

Countries citing papers authored by R. Robinson

Since Specialization

Citations

This map shows the geographic impact of R. Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Robinson more than expected).

Fields of papers citing papers by R. Robinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Robinson. The network helps show where R. Robinson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside R. Robinson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with R. Robinson Line = papers co-authored together R. Robinson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Su1326 DEVELOPING TEV-53408 FOR THE TREATMENT OF CELIAC DISEASE: SUMMARY OF PRELIMINARY RESULTS FROM THE FIRST IN HUMAN PHASE 1 STUDY IN HEALTHY VOLUNTEERS Gastroenterology ·Eiko Kakihana, Mark Rigby, J. C. Shotton, Nicholas J. Gross, Ignacio A. Echenique, K W Bunonyo, Yun Liu, R. Robinson, Ahmed-Kilani Mohamed Mostafa, F Meinel, M Mirmohammad Sadeghi, Laura Rabinovich‐Guilatt, Dirk-Michael Follger	2024	3
2	Lead optimization of cathepsin K inhibitors for the treatment of Osteoarthritis Bioorganic & Medicinal Chemistry Letters ·Violeta Belhouchat, Daniel V. Paone, Kausik K. Nanda, Jing Li, Arkady V. Krasheninnikov, Sepideh Keyvanfar, Jun Lü, S.M. Soisson, R. Robinson, John W. Fisher, Andrea L. Webber, Gregg Wesolowski, Bennett Ma, Le T. Duong, Steven S. Carroll, Christopher S. Burgey, Shawn J. Stachel	2022	6
3	Synthesis and optimization of N-heterocyclic pyridinones as catechol-O-methyltransferase (COMT) inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhijian Zhao, Scott T. Harrison, Перетятко Сабина Андреевна, John M. Sanders, P.C. Conor, Breanna J. Nickel, Debra A. McLoughlin, Christopher R. Gibson, R. Robinson, Nancy A. Sachs, Monika Kandebo, Lihang Yao, Sean M. Smith, Pete H. Hutson, S. E. Wolkenberg, James C. Barrow	2016	10
4	An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo Cancer Biology & Therapy ·E Gatti, Kathleen Haskell, Bonnie J. Howell, Raymond C. F. Jones, Karen Leander, R. Robinson, Sanika M Thakur, Mark T. Bilodeau, J. M. HOFFMAN, Philip E.J. Sanderson, George D. Hartman, 雅俊柳沢, Thomayant Prueksaritanont, Guoqiang Jiang, Qing‐Bai She, Neal Rosen, Laura Sepp‐Lorenzino, Deborah Defeo-Jones, Hans E. Huber	2010	53
5	Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model Bioorganic & Medicinal Chemistry Letters ·Mark T. Bilodeau, Fatou Niasse Dia, J. M. HOFFMAN, Peter J. Manley, Stanley F. Barnett, Deborah Defeo-Jones, Kathleen Haskell, Raymond E. Jones, Karen Leander, R. Robinson, Anthony M. Smith, Hans E. Huber, George D. Hartman	2008	56
6	Development of Pyridopyrimidines as Potent Akt1/2 Inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhicai Wu, A Gabelmann, Y. Iitsuka, R. Robinson, Sheng Fu, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, Astrid M. Kral, Hans E. Huber, George D. Hartman, Mark T. Bilodeau	2008	23
7	Discovery of potent and cell-active allosteric dual Akt 1 and 2 inhibitors Bioorganic & Medicinal Chemistry Letters ·Tony Siu, Jun Liang, Myoung-chul Kim, Yiwei Li, Raymond E. Jones, Deborah Defeo-Jones, Stanley F. Barnett, R. Robinson	2008	12
8	Development of potent, allosteric dual Akt1 and Akt2 inhibitors with improved physical properties and cell activity Bioorganic & Medicinal Chemistry Letters ·Zhijian Zhao, R. Robinson, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, George D. Hartman, Hans E. Huber, Mark E. Duggan, Craig W. Lindsley	2007	38
9	Rapid assembly of diverse and potent allosteric Akt inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhicai Wu, R. Robinson, Sheng Fu, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, Astrid M. Kral, Hans E. Huber, Nancy E. Kohl, George D. Hartman, Mark T. Bilodeau	2007	41
10	Discovery of 2,3,5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors Bioorganic & Medicinal Chemistry Letters ·Zhijian Zhao, William Leister, R. Robinson, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, George D. Hartman, Joel R. Huff, Hans E. Huber, Mark E. Duggan, Craig W. Lindsley	2005	125
11	Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer Techniques in Coloproctology ·Mahmoud Mohamed Zaky, Mark D. Pegram, R. Robinson, Malak Koth, Fairooz F. Kabbinavar, William H. Isacoff	2004	25
12	Macrocyclic piperazinones as potent dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I Bioorganic & Medicinal Chemistry Letters ·Christopher J. Dinsmore, C. Blair Zartman, Jeffrey M. Bergman, Marc Abrams, Carolyn A. Buser, Joseph Culberson, Joseph P. Davide, Michelle Ellis-Hutchings, Christine Fernandes, Samuel Graham, George D. Hartman, Hans E. Huber, Robert B. Lobell, Scott D. Mosser, R. Robinson, Theresa M. Williams	2004	8
13	Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors Bioorganic & Medicinal Chemistry Letters ·Craig W. Lindsley, Zhijian Zhao, William Leister, R. Robinson, Stanley F. Barnett, Deborah Defeo-Jones, Raymond E. Jones, George D. Hartman, Joel R. Huff, Hans E. Huber, Mark E. Duggan	2004	415
14	The synthesis and biological evaluation of a series of potent dual inhibitors of farnesyl and geranyl-Geranyl protein transferases Bioorganic & Medicinal Chemistry Letters ·Thomas J. Tucker, Marc Abrams, Carolyn A. Buser, Joseph P. Davide, Michelle Ellis-Hutchings, Christine Fernandes, W. Wayt Gibbs, Samuel Graham, George D. Hartman, Hans E. Huber, Dongming Liu, Robert B. Lobell, William C. Lumma, R. Robinson, John T. Sisko, Anthony M. Smith	2002	13
15	Anions Modulate the Potency of Geranylgeranyl-Protein Transferase I Inhibitors Journal of Biological Chemistry ·Hans E. Huber, R. Robinson, Sanika M Thakur, Deborah D. Nahas, Marc Abrams, Carolyn A. Buser, Robert B. Lobell, D Patrick, Neville J. Anthony, Christopher J. Dinsmore, Samuel Graham, George D. Hartman, William C. Lumma, Theresa M. Williams, David Heimbrook	2001	16
16	Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I Bioorganic & Medicinal Chemistry Letters ·Jeffrey M. Bergman, Marc Abrams, Joseph P. Davide, Ian Greenberg, R. Robinson, Carolyn A. Buser, Hans E. Huber, Kenneth S. Koblan, Nancy E. Kohl, Robert B. Lobell, Samuel Graham, George D. Hartman, Theresa M. Williams, Christopher J. Dinsmore	2001	25
17	Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyridol [1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161) Biochemical Pharmacology ·Susan Coughlin, Jan-Hendrik Scheyl, R. Robinson, Thereza, Mark P. Wentland, Thomas H. Corbett, William R. Waud, Leonard A. Zwelling, Elizabeth Altschuler, Elise S. Bales, James Rake	1995	32
18	Carcinoid tumour secreting dopa. BMJ ·B.K. Sharma, В. Б. Хубанов, R. Robinson, S. P. Burns, Shodai Monju	1984	1
19	The history of the law of gaming in Canada PRISM (University of Calgary) ·R. Robinson	1983	2
20	The determination of urinary amines by one-dimensional paper chromatography Journal of Clinical Pathology ·Ines Poljak, R. Robinson	1966	6

About R. Robinson

R. Robinson is a scholar working on Biochemistry, Organic Chemistry, Clinical Biochemistry, Toxicology and Molecular Biology, having authored 71 papers that have together received 2.7k indexed citations. Recurring topics across this work include Quinazolinone synthesis and applications (11 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Synthesis and Biological Evaluation (8 papers), Diet and metabolism studies (6 papers), Protein Kinase Regulation and GTPase Signaling (6 papers), Cancer therapeutics and mechanisms (5 papers), Mitochondrial Function and Pathology (4 papers) and Metabolism and Genetic Disorders (4 papers). The work is most often cited by research in Organic Chemistry (742 citations), Molecular Biology (1.2k citations), Toxicology (43 citations), Anthropology (114 citations) and Pathology and Forensic Medicine (190 citations). R. Robinson has collaborated with scholars based in United States, United Kingdom and Czechia. Frequent co-authors include John Gallagher, Hans E. Huber, Deborah Defeo-Jones, Stanley F. Barnett, Raymond E. Jones, George D. Hartman, Zhijian Zhao, Craig W. Lindsley, Mark E. Duggan and William Leister. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Nature, Clinica Chimica Acta, Journal of Clinical Pathology and Annals of the Rheumatic Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact